Share on Pinterest Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Shelby Knowles/Bloomberg/Getty Images Zepbound outperformed ...

For the study, researchers randomly assigned 751 participants with obesity but not Type 2 diabetes to take either tirzepatide, aka Zepbound, or semaglutide, aka Wegovy, weekly, for 72 weeks.

And one clearly comes out on top. Injectable GLP-1 receptor agonist drugs Wegovy (semaglutide) and Zepbound (tirzepatide) have revolutionized weight loss. But, strangely, no one has compared the ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

A study, published Sunday in the New England Journal of Medicine, found tirzepatide users lost about 20% of their body weight, whereas those on semaglutide ... the maker of Wegovy and Ozempic ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.